STAT

At Harvard forum, three who know warn of ‘most daunting virus’ in half a century

Few people have immunity to the new coronavirus. "The potential for this to burn through a population very quickly is very high without extraordinary measures."

CAMBRIDGE, Mass. — For a veteran epidemiologist, an authority on homeland security, and a global health reporter, the outbreak of the novel coronavirus is the type of emergency they had long anticipated. But now that it is here, the three experts said Friday, they still couldn’t help but feel the monumentality of what they were watching unfold.

“It’s the most daunting virus that we’ve contended with in half a century or more,” Michael Mina, an epidemiologist at Harvard’s T.H. Chan School of Public Health, said at a panel discussion Friday at Harvard’s Kennedy School of Government.

Helen Branswell, STAT’s infectious diseases and public health reporter, has covered emerging pathogens since the 2003 SARS outbreak.

But with the new coronavirus, Branswell said during the panel, “It’s bizarre but I find myself startled. Having written about the possibility of something like this for years, I still find myself really startled that it’s happening, and I don’t know why that is.”

She compared the circumstances now to the summer of 2014, when Ebola was racing through West Africa and

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks